Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy

Background: VPM1002BC is a modified mycobacterium Bacillus Calmette Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC). The genetic modifications are expected to result in better immunogenicity and less side effects. We report on patient safety and immunology of the first i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rentsch, Cyrill A., Bosshard, Piet, Mayor, Grégoire, Rieken, Malte, Püschel, Heike, Wirth, Grégory, Cathomas, Richard, Parzmair, Gerald P., Grode, Leander, Eisele, Bernd, Sharma, Hitt, Gupta, Manish, Gairola, Sunil, Shaligram, Umesh, Goldenberger, Daniel, Spertini, François, Audran, Régine, Enoiu, Milica, Berardi, Simona, Hayoz, Stefanie, Wicki, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185202/
https://www.ncbi.nlm.nih.gov/pubmed/32363120
http://dx.doi.org/10.1080/2162402X.2020.1748981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185202/
https://www.ncbi.nlm.nih.gov/pubmed/32363120
http://dx.doi.org/10.1080/2162402X.2020.1748981

Ejemplares similares